Pediatric epilepsy: addressing heterogeneity to improve treatment development

The future of pediatric epilepsy therapy development relies on the improved use of biomarkers, precision medicine, and novel trial designs, according to an expert presenting at CNS 2021.

Dr Adam Hartman, program director of the Division of Clinical Research at the National Institute of Neurological Disorders and Stroke/National Institutes of Health (NINDS/NIH), pointed out that the key issue to address in order to aid clinical development is the heterogeneity of the patient population in pediatric epilepsy.